Get the Stockscreener App
32.89
2.11%
-0.71
Neurogene Inc stock is traded at $32.89, with a volume of 162.88K.
It is down -2.11% in the last 24 hours and up +4.58% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$33.60
Open:
$33.5
24h Volume:
162.88K
Relative Volume:
0.79
Market Cap:
$656.17M
Revenue:
$925.00K
Net Income/Loss:
$-98.64M
P/E Ratio:
-6.553
EPS:
-5.0191
Net Cash Flow:
$-83.37M
1W Performance:
-5.76%
1M Performance:
+4.58%
6M Performance:
+86.24%
1Y Performance:
+51.08%
1-Day Range:
$31.82
$33.63
1-Week Range:
$31.82
$35.92
52-Week Range:
$15.93
$43.66
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
32.89 | 690.68M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene Inc (NGNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurogene Inc (NGNE) Institutional Confidence - TradingKey
NGNE|Neurogene Inc|Price:34.610|Chg%:-0.290 - TradingKey
Neurogene Inc (NGNE) Cash Flow - TradingKey
Neurogene Inc (NGNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurogene Inc (NGNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurogene Inc (NGNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ETFs Investing in Neurogene Inc. Stocks - TradingView
TradingKey - TradingKey
Neurogene Inc (NGNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurogene Completes $143.7 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
Neurogene prices $125M equity offering - MSN
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss and No Revenue Highlight Pre-Commercial Challenges - dars.gov.et
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Advances Pivotal Gene Therapy Trial, Embodying Houston's Dynamic Life Sciences Ecosystem - Greater Houston Partnership
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews
Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News
Neurogene president & CFO Cvijic sells $173,375 in stock - Investing.com
Insider Sell: Christine Cvijic Sells 4,800 Shares of Neurogene I - GuruFocus
Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Nigeria
Form 4 Neurogene Inc For: 7 July By Investing.com - Investing.com Nigeria
Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65 - Moomoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene announces pricing of $125 million public offering - The Pharma Letter
Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa
Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com
Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView
Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
Neurogene bolsters cash runway with equity offering - TipRanks
Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa
Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan
Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView
Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia
Neurogene prices $125 million public offering at $30 per share - Investing.com
Neurogene Sets Pricing For $125 Million Public Offering - TradingView
Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada
Neurogene Prices $125 Million Public Offering - marketscreener.com
Neurogene Inc Stock (NGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurogene Inc Stock (NGNE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Jul 06 '26 |
Sale |
36.02 |
600 |
21,613 |
88,240 |
| Cvijic Christine Mikail | President and CFO |
Jul 02 '26 |
Sale |
34.82 |
4,061 |
141,417 |
88,840 |
| Cvijic Christine Mikail | President and CFO |
Jul 01 '26 |
Sale |
34.06 |
739 |
25,170 |
92,901 |
| Cvijic Christine Mikail | President and CFO |
May 06 '26 |
Sale |
31.25 |
9,600 |
300,043 |
93,640 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):